Pharmacogenomics is the study of genetic variations that influence an individual’s response to drugs. Pharmacogenomics is the combination of pharmacology and genomics. Pharmacology is the part of science that studies how drugs work. Genomics is the study of a person’s genome including the interactions of those genes with each other and with the person’s environment. Each person responds uniquely to treatment, while one treatment approach may work well for one individual, the same approach may not be effective or may cause adverse drug effects in other patients. The implementation of pharmacogenomics helps physicians make informed treatment decisions. This will lead to better outcomes by decreasing adverse drug events and by increasing the effectiveness of drugs.
Pharmacogenomics testing is recommended for any patient who is taking multiple medications, experienced pharmacotherapeutic failure, had a severe adverse drug reaction or complications due to ADEs, and taking medications with FDA’s require/recommend PGx testing.
Pharmacogenomics testing is also recommended for polypharmacy patients and any patient who is receiving drug treatment.
PGxOne™ Plus provides comprehensive coverage. It assays 53 genes in a single test covering over 310 medical condition and 20 therapeutic areas including cardiology, oncology, pain management, and psychiatry. It detects around 200 variants and provides recommendations for over 300 commercial drugs. PGxOne™ Plus utilizes the most advanced technology NGS, provides medically actionable and clinically relevant data. NGS delivers comprehensive genetic variant coverage and capable of detecting Copy Number Variations, deletions, insertions, and substitutions. It applies proprietary bioinformatics methodologies for data analysis and interpretation. The process is easy and convenient and has a fast turn-around-time.
PharmGKB is a pharmacogenomics knowledge resource that encompasses clinical information including dosing guidelines and drug labels, potentially clinically actionable gene-drug associations and genotype-phenotype relationships.
PGxOne™ Plus is a comprehensive report with specific sections driven by ICD 10 codes and current medications.
PGxPsych™ is a specialty report highlighting psychiatric drugs with favorable recommendations in the first section of the report.
PGxOnco™ is a specialty report with specific sections for drugs commonly used in cancer supportive care and chemotherapeutics.
PGxCardio™ is a cardio branded report.
All reports are all-inclusive, have ICD-10 & current medication driven sections, and available in Spanish.
Specific submission requirements are as follows: PGxOne™ Plus testing uses DNA isolated from buccal swabs, mouthwash/oral rinse, blood or saliva.
Buccal Swabs: Two buccal swabs are provided in the test supplies sent to the physician by Admera Health. Both swabs should be used to obtain buccal cells from the patient’s cheeks according to the instructions provided. The swabs should be placed into the collection tube as indicated.
Mouthwash/Oral Rinse: Scope mouthwash, measuring cup, and collection tube are provided to the Physician. Fill the measuring cup near the top with mouthwash. Swish vigorously for at least 15 seconds then spot all the mouthwash from your mouth to the collection tube. Repeat twice to ensure the collection tube is filled at least to the 40ml lines.
Blood: DNA blood tube is provided to the Physician. Draw at least 2mls of blood in lavender top vacutainer, which contains EDTA as an anticoagulant. Immediately invert the tube 8 to 10 times to ensure mixing and anticoagulation of the samples.
Saliva: One saliva collection supply is provided to the physician. The tube must be filled with saliva to the black wavy line as detailed in the provided instructions. Following collection, tighten the cap and shake the tube for at least five seconds to ensure proper mixing of the saliva with the stabilizing solutions.
Oncology Testing Portfolio:
Admera Health’s oncology tumor profiling tests sequence multiple genes or specific locations on genes at one time to determine the presence of known cancer-causing mutations, including single nucleotide variants, insertions and deletions, copy number variants, and fusions. Most other testing modalities are not comprehensive, interrogating for only one gene or protein, and are not able to detect the presence of multiple mutation types.
OncoGxOne™, is Admera’s most comprehensive clinical tumor profiling Next Generation Sequencing panel available, including 56 genes linked to cancer.
OncoGxSelect™ is a narrower Next Generation Sequencing panel that is designed to align with nationally established cancer guidelines.
LiguidGx™ is also used to detect cancer-driving mutations but from a blood sample. Two testing modalities are available, a proprietary qPCR method and a Next Generation Sequencing panel based on need/preference.
Admera’s tumor profiling tests can detect the presence of known mutations for patients that have been diagnosed with cancer, specifically solid tumors. With this knowledge, Admera can provide recommendations on which targeted therapies are likely to be beneficial and which ones are not. Relevant clinical trial information based on geography will also be provided (five clinical trials/mutation found). In some cases, in addition to targeted therapy recommendations, prognosis information related to the mutation/s detected is available.
Fragments of DNA, called cell-free DNA (cfDNA), circulate freely in the blood. ctDNA (circulating tumor DNA) is a type of cfDNA that has been shed of off tumors into the bloodstream. ctDNA can be used to detect known mutations associated with some types of cancer. LiquidGx™ also detects ctRNA for fusion detection.
Cardiovascular Testing Portfolio:
Blood: A lavender top vacutainer tube containing ETDA is used to collect up to 5mls of blood. Following collection, invert the sample tube 8 to 10 times to ensure proper mixing. Please note blood samples should be shipped with the enclosed cold pack.
PGxOne™ Plus test results will typically be available within 7-10 business days following receipt of the sample at our lab.
LiquidGx™ test results will typically be available within three days for qPCR tests and 3-5 for NGS tests.
OncoGxOne™ and OncoGxSelect™ test results will typically be available within 7-10 business days following receipt of the sample at our lab.
CarioGxOne™ and AtheroGxOne™ test results will typically be available in 3-4 weeks following receipt of the patient samples.
To confirm coverage by your insurance provider, please call Admera Health Billing
Phone: 1-908-222-0533; press option 2
Please call 1-908-222-0533, option 2 for any billing questions
Alternatively, Admera Health has partnered with a logistics company that tracks supply volume via barcode scanning and will automatically replenish inventory once 70% of the supplies have been utilized.